Rubicon Research Quarterly Results for Trading Insights
In Sept 2025, Rubicon Research (RUBICON) reported revenue ₹413 Cr and net profit ₹54 Cr — revenue +38.1% YoY. Compare with RUBICON stock valuation models to assess whether the stock is under or overvalued.
RUBICON Quarterly Results — Revenue, Profit & EPS Highlights
Rubicon Research latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore RUBICON price trends to track price trends across different timeframes.
- Revenue of ₹413 Cr in Sept 2025 (+15.4% vs Mar 2025, +38.1% vs Sept 2024)
- Net Profit of ₹54 Cr in Sept 2025 (+50.0% vs Mar 2025, +54.3% vs Sept 2024)
- EBITDA of ₹95 Cr in Sept 2025 (+30.1% vs Mar 2025)
- Operating Margin of 23.0% in Sept 2025 (+3.0pp vs Mar 2025)
- Earnings Per Share of ₹3.49 in Sept 2025 (+48.5% vs Mar 2025)
Rubicon Research Quarterly Results — Revenue, EBITDA, Net Profit & EPS
RUBICON quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 413 | 358 | 353 | 479 | 299 | 15.4% | 38.1% |
| Net Profit (₹ Cr) | 54 | 36 | 43 | 73 | 35 | - | - |
| EBITDA (₹ Cr) | 95 | 73 | 80 | 112 | 64 | - | - |
| EPS (₹) | 3.49 | 2.35 | 2.81 | 4.46 | 2.27 | - | - |
| Operating Margin (%) | 23.0% | 20.0% | 22.0% | 23.0% | 21.0% | - | - |
RUBICON Share Price Trend — 1-Year Movement Across Quarterly Results
Rubicon Research 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Rubicon Research share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
RUBICON vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Rubicon Research latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1840.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 162.9 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6753.0 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 238.5 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹151,833.39 Cr | 4452.1 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 386.8 |
|
Cipla
Mar 2026 |
₹113,024.67 Cr | 1417.5 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.3 |
|
Dr Reddys Laborator…
Mar 2026 |
₹109,104.54 Cr | 1327.9 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 501.1 |
All amounts in ₹ Crores